Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Abstract Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor-positive (ER+) breast cancer. Understanding the resistance mechanisms and identifying reliable predictive biomark...
Sparad:
| Huvudupphov: | , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Nature Portfolio
2022-09-01
|
| Serie: | npj Precision Oncology |
| Länkar: | https://doi.org/10.1038/s41698-022-00311-6 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|